Jade Biosciences, Inc. (JBIO) shareholders
Close on Nov 17, 2026Market cap $979.40MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Evan Harwin Joint filing with Fairmount Funds Management LLC (19.99%), Tomas Kiselak (19.99%) and 1 more | 14,069,494 | 19.99% | 13D (active) amendment | Jun 5, 2026 |
| Tomas Kiselak Joint filing with Fairmount Funds Management LLC (19.99%), Peter Evan Harwin (19.99%) and 2 more | 7,249,356 | 19.99% | 13D (active) | Apr 28, 2025 |
| JANUS HENDERSON GROUP Ltd. | 6,273,262 | 10.60% | 13G (passive) amendment | Jun 30, 2026 |
| VHCP Co-Investment Holdings III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (8.30%), Venrock Healthcare Capital Partners EG, L.P. (8.30%) and 4 more | 5,145,330 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (14.70%) | 4,735,951 | 14.70% | 13G (passive) | May 30, 2025 |
| Franklin Templeton, Inc. | 3,807,236 | 6.00% | 13G (passive) | Sep 30, 2026 |
| BlackRock, Inc. | 3,323,301 | 5.20% | 13G (passive) | Sep 30, 2026 |
| VHCP Management EG, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 3,220,369 | 9.90% | 13G (passive) | Apr 28, 2025 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (7.00%), Rajeev Shah (7.00%) and 1 more | 3,214,969 | 7.00% | 13G (passive) | Oct 8, 2025 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (5.10%), Senai Asefaw, M.D. (5.10%) | 3,106,793 | 5.10% | 13G (passive) | Jul 10, 2026 |
| Janus Henderson Group PLC | 3,105,669 | 6.30% | 13G (passive) amendment | Mar 31, 2026 |
| Bellevue Asset Management AG Joint filing with Bellevue Group AG (5.00%) | 3,057,996 | 5.00% | 13G (passive) amendment | Jun 30, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (8.64%), David Kroin (8.64%) | 2,784,648 | 8.64% | 13G (passive) | Apr 28, 2025 |
| David Kroin Joint filing with Deep Track Capital, LP (6.99%), Deep Track Biotechnology Master Fund, Ltd. (6.99%) | 2,279,892 | 6.99% | 13G (passive) amendment | Sep 30, 2025 |
| Patrick J. Heron Joint filing with James N. Topper (5.50%), Albert Cha (5.40%) and 1 more | 1,772,116 | 5.50% | 13G (passive) | Apr 28, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,126,877 | 14.35% | $202.80M | +2,041,454 | 0.01% |
| Jupiter Topco LLC | 6,273,262 | 9.86% | $139.37M | New | 0.06% |
| Fairmount Funds Management LLC | 4,553,494 | 7.16% | $101.18M | – | 6.69% |
| Ra Capital Management, L.P. | 3,671,083 | 5.77% | $81.57M | – | 0.71% |
| VR Adviser, LLC | 3,220,364 | 5.06% | $71.56M | – | 2.17% |
| Bellevue Group AG | 3,057,996 | 4.81% | $67.95M | −443,506 | 1.43% |
| Paradigm Biocapital Advisors LP | 2,857,405 | 4.49% | $63.49M | New | 1.19% |
| BlackRock, Inc. | 2,801,451 | 4.40% | $62.25M | +487,502 | 0.00% |
| Franklin Resources Inc | 2,792,080 | 4.39% | $62.04M | New | 0.01% |
| State Street Corp | 2,335,285 | 3.67% | $51.89M | +1,679,595 | 0.00% |
| Vanguard Capital Management LLC | 2,244,773 | 3.53% | $49.88M | +448,121 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 1,910,812 | 3.00% | $42.46M | New | 0.06% |
| Polar Capital Holdings Plc | 1,846,982 | 2.90% | $41.04M | New | 0.10% |
| Avidity Partners Management LP | 1,700,708 | 2.67% | $37.79M | −1,100,708 | 6.05% |
| Remedium Capital Partners, LLC | 1,577,750 | 2.48% | $35.06M | – | 7.76% |
| Soleus Capital Management, L.P. | 1,550,690 | 2.44% | $34.46M | +753,946 | 1.19% |
| JPMorgan Chase & Co | 1,475,079 | 2.32% | $32.61M | +1,459,216 | 0.00% |
| Baker Bros. Advisors LP | 1,230,426 | 1.93% | $27.34M | −410,711 | 0.14% |
| Logos Global Management LP | 1,125,000 | 1.77% | $25.00M | +725,000 | 1.08% |
| Versant Venture Management, LLC | 991,783 | 1.56% | $22.04M | −534,037 | 13.55% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 154 | 73M | 100.0% | 52 / 60 | 26 / 16 | 31M | 7M |
| Q1 2026 | 120 | 51M | 80.8% | 29 / 39 | 33 / 13 | 10M | 4M |
| Q4 2025 | 105 | 47M | 74.0% | 33 / 43 | 15 / 6 | 20M | 5M |
| Q3 2025 | 78 | 32M | 49.7% | 8 / 23 | 22 / 3 | 1M | 1M |
| Q2 2025 | 73 | 32M | 49.6% | 73 / 0 | 0 / 0 | 32M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
126 funds held JBIO in Q2 2026, 37% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of JBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,699,343 | 2.67% | $37.76M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,533,573 | 2.41% | $34.08M | 0.32% | Jun 30, 2026 |
| Franklin Small Cap Value Fund | 1,412,559 | 2.22% | $27.90M | 0.65% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 1,009,957 | 1.59% | $21.25M | 0.02% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 908,146 | 1.43% | $17.94M | 0.24% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 852,070 | 1.34% | $18.93M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 779,915 | 1.23% | $15.40M | 0.18% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 716,799 | 1.13% | $15.93M | 0.27% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 698,671 | 1.10% | $13.80M | 0.63% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund | 677,766 | 1.07% | $15.06M | 0.58% | Jun 30, 2026 |
| Select Health Care Portfolio | 640,000 | 1.01% | $13.47M | 0.23% | May 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 589,200 | 0.93% | $11.64M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 484,964 | 0.76% | $10.78M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 479,949 | 0.75% | $9.48M | 0.82% | Jul 31, 2026 |
| Franklin Small Cap Growth Fund | 432,709 | 0.68% | $8.55M | 0.35% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Tom Frohlich | Chief Executive Officer, Director | 86,331 | 0.14% | Feb 13, 2026 |
| Elizabeth Balta | See Remarks | 28,125 | 0.04% | Feb 13, 2026 |
| Bradford D. Dahms | Chief Financial Officer | 37,813 | 0.06% | Feb 13, 2026 |
| Andrew James King | See Remarks | 386,113 | 0.61% | Feb 13, 2026 |
| Hetal Kocinsky | Chief Medical Officer | – | – | May 1, 2025 |
| Jonathan Quick | See Remarks | – | – | May 1, 2025 |
| Mark Eisner | Director | – | – | Jun 26, 2026 |
| Eric Dobmeier | Director | – | – | Jun 11, 2026 |
| Erin Lavelle | Director | – | – | Jun 11, 2026 |
| Healthcare Co-Invest IV L.P. Fairmount | Director, 10% owner | – | – | Jun 11, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 4,553,494 | 7.16% | Jun 11, 2026 |
| Tomas Kiselak | Director, 10% owner | – | – | Jun 11, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Jun 11, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Jun 11, 2026 |
| Lawrence Otto Klein | Director | 86,215 | 0.14% | Jun 11, 2026 |
| Christopher W. Cain | Director | – | – | Jun 11, 2026 |
| Ra Capital Management, L.P. | 10% owner | – | – | Apr 30, 2025 |
| Peter Kolchinsky | 10% owner | 1,287,858 | 2.03% | Apr 30, 2025 |
| Rajeev M. Shah | 10% owner | 7,893,678 | 12.41% | Apr 30, 2025 |
| Capital Healthcare Fund LP RA | 10% owner | – | – | Apr 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bradford D. Dahms Chief Financial Officer | Feb 12, 2026 | Award | +37,813 | – | – | 37,813 |
| Tom Frohlich Chief Executive Officer, Director | Feb 12, 2026 | Award | +78,750 | – | – | 86,331 |
| Andrew James King See Remarks | Feb 12, 2026 | Award | +41,250 | – | – | 386,113 |
| Elizabeth Balta See Remarks | Feb 12, 2026 | Award | +28,125 | – | – | 28,125 |
| Healthcare Fund II L.P. Fairmount Director, 10% owner | Oct 6, 2025 | Award | +1,333,126 | $9.14 | $12.18M | 1,897,677 |
| Tom Frohlich Chief Executive Officer, Director | May 16, 2025 | Buy | +6,000 | $7.40 | $44.40K | 6,000 |
| Peter Kolchinsky 10% owner | Apr 28, 2025 | Other | +1,062,326 | – | – | 1,287,858 |
| Benjamin T. Dake SEE REMARKS | Aug 1, 2024 | Option exercise | +1,507 | $1.74 | $2.62K | 14,252 |
| Benjamin T. Dake SEE REMARKS | Jul 31, 2024 | Option exercise | +11,454 | $1.74 | $19.93K | 12,745 |
| Rajeev M. Shah Director, 10% owner | Jun 17, 2024 | Buy | +928,110 | $1.67 | $1.55M | 7,893,678 |
| George A. Eldridge SEE REMARKS | Jun 14, 2024 | Option exercise | +15,000 | $2.14 | $32.10K | 20,022 |
| George A. Eldridge SEE REMARKS | Jun 14, 2024 | Sale(10b5-1 plan) | −15,000 | $25.03 | $375.45K | 5,022 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Jun 14, 2024 | Option exercise | +10,600 | $14.59 | $154.65K | 10,600 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Jun 14, 2024 | Sale(10b5-1 plan) | −10,600 | $25.00 | $265.00K | 0 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Jun 13, 2024 | Option exercise | +6,000 | $2.14 | $12.84K | 11,602 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Jun 13, 2024 | Sale(10b5-1 plan) | −6,000 | $24.50 | $147.00K | 5,602 |
| Hunter Gillies CHIEF MEDICAL OFFICER | May 17, 2024 | Option exercise | +4,000 | $2.14 | $8.56K | 9,602 |
| Hunter Gillies CHIEF MEDICAL OFFICER | May 17, 2024 | Sale(10b5-1 plan) | −3,914 | $21.07 | $82.47K | 5,688 |
| Hunter Gillies CHIEF MEDICAL OFFICER | May 17, 2024 | Sale(10b5-1 plan) | −86 | $21.86 | $1.88K | 5,602 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 16, 2024 | Sale(10b5-1 plan) | −8,707 | $21.52 | $187.37K | 1,293 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 16, 2024 | Sale(10b5-1 plan) | −1,293 | $21.92 | $28.34K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 16, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | May 2, 2024 | Sale | −1,981 | $21.02 | $41.64K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Sale(10b5-1 plan) | −1,357 | $19.91 | $27.02K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Sale(10b5-1 plan) | −965 | $20.87 | $20.14K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Sale(10b5-1 plan) | −9,035 | $20.34 | $183.77K | 965 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | May 1, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Apr 17, 2024 | Sale(10b5-1 plan) | −3,689 | $22.30 | $82.26K | 3,562 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Apr 17, 2024 | Option exercise | +4,000 | $1.74 | $6.96K | 7,251 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Apr 17, 2024 | Sale(10b5-1 plan) | −311 | $23.33 | $7.26K | 3,251 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Option exercise | +6,853 | $2.14 | $14.67K | 8,144 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Sale(10b5-1 plan) | −338 | $23.17 | $7.83K | 1,359 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Sale(10b5-1 plan) | −68 | $23.97 | $1.63K | 1,291 |
| Benjamin T. Dake SEE REMARKS | Apr 17, 2024 | Sale(10b5-1 plan) | −6,447 | $22.32 | $143.90K | 1,697 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 16, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 16, 2024 | Sale(10b5-1 plan) | −4,491 | $24.40 | $109.58K | 5,509 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 16, 2024 | Sale(10b5-1 plan) | −5,509 | $24.94 | $137.39K | 0 |
| George A. Eldridge SEE REMARKS | Apr 10, 2024 | Option exercise | +7,500 | $2.14 | $16.05K | 9,460 |
| George A. Eldridge SEE REMARKS | Apr 10, 2024 | Sale(10b5-1 plan) | −6,729 | $26.77 | $180.14K | 2,731 |
| George A. Eldridge SEE REMARKS | Apr 10, 2024 | Sale(10b5-1 plan) | −771 | $27.56 | $21.25K | 1,960 |
| David S. Grayzel Director | Apr 9, 2024 | Sale | −11,882 | $28.15 | $334.48K | 14,502 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Apr 1, 2024 | Option exercise | +5,300 | $14.59 | $77.33K | 5,300 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Apr 1, 2024 | Sale(10b5-1 plan) | −1,504 | $30.00 | $45.12K | 0 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Apr 1, 2024 | Sale(10b5-1 plan) | −3,796 | $28.87 | $109.59K | 1,504 |
| Benjamin T. Dake SEE REMARKS | Apr 1, 2024 | Option exercise | +3,325 | $10.61 | $35.28K | 4,616 |
| Benjamin T. Dake SEE REMARKS | Apr 1, 2024 | Sale(10b5-1 plan) | −3,325 | $31.97 | $106.30K | 1,291 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −1,647 | $29.90 | $49.25K | 3,851 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −4,502 | $28.96 | $130.38K | 5,498 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Option exercise | +10,000 | $2.14 | $21.40K | 10,000 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −1,000 | $31.95 | $31.95K | 0 |
| Timothy P. Noyes CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −2,851 | $31.02 | $88.44K | 1,000 |
| George A. Eldridge SEE REMARKS | Apr 1, 2024 | Sale(10b5-1 plan) | −12,495 | $31.23 | $390.22K | 1,960 |
| George A. Eldridge SEE REMARKS | Apr 1, 2024 | Option exercise | +12,495 | $2.14 | $26.74K | 14,455 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Mar 28, 2024 | Option exercise | +9,000 | $2.14 | $19.26K | 12,251 |
| Hunter Gillies CHIEF MEDICAL OFFICER | Mar 28, 2024 | Sale(10b5-1 plan) | −9,000 | $29.50 | $265.50K | 3,251 |
| Benjamin T. Dake SEE REMARKS | Mar 27, 2024 | Sale(10b5-1 plan) | −11,068 | $27.97 | $309.57K | 1,291 |
| Benjamin T. Dake SEE REMARKS | Mar 27, 2024 | Option exercise | +11,068 | $10.61 | $117.43K | 12,359 |
| Benjamin T. Dake SEE REMARKS | Mar 25, 2024 | Sale(10b5-1 plan) | −3,432 | $28.01 | $96.13K | 1,291 |
| Benjamin T. Dake SEE REMARKS | Mar 25, 2024 | Option exercise | +3,432 | $10.61 | $36.41K | 4,723 |
| Marinus Verwijs CHIEF TECHNICAL OFFICER | Mar 19, 2024 | Sale(10b5-1 plan) | −2,764 | $26.46 | $73.14K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jade Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,535 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Atlas Venture Associates XII, L.P. Shareholder | Jun 25, 2025 | 235 | $2.46K | Jun 25, 2025 | Private Placement |
| Atlas Venture Fund XII, L.P. Shareholder | Jun 25, 2025 | 28,977 | $303.68K | Jun 25, 2025 | Private Placement |
| Atlas Venture Fund XII, L.P. Shareholder | Jun 24, 2025 | 16,132 | $159.22K | Jun 24, 2025 | Private Placement |
| Atlas Venture Associates XII, L.P. Shareholder | Jun 24, 2025 | 131 | $1.29K | Jun 24, 2025 | Private Placement |
| Atlas Venture Fund XII, L.P. Shareholder | May 6, 2025 | 5,883 | $67.65K | May 6, 2025 | Private Placement |
| Atlas Venture Associates XII, L.P. Shareholder | May 6, 2025 | 48 | $552 | May 6, 2025 | Private Placement |
| Marinus Verwijs Officer | Jun 14, 2024 | 10,600 | $265.00K | Jun 14, 2024 | Stock Option Exercise |
| Hunter Gillies Officer | Jun 13, 2024 | 6,000 | $147.00K | Jun 13, 2024 | Stock Option Exercise |
| Hunter Gillies Officer | May 17, 2024 | 4,000 | $84.33K | May 17, 2024 | Stock Option Exercise |
| Timothy P. Noyes Officer, Director | May 16, 2024 | 10,000 | $215.76K | May 16, 2024 | Stock Option Exercise |
| Marinus Verwijs Officer | May 2, 2024 | 1,981 | $41.63K | May 2, 2024 | ESPP |
| Timothy P. Noyes Officer, Director | May 1, 2024 | 11,357 | $230.94K | May 1, 2024 | Employee Stock Purchase Plan |
| Benjamin T. Dake Officer | Apr 17, 2024 | 6,853 | $161.87K | Apr 17, 2024 | Options Grant |
| Hunter Gillies Officer | Apr 17, 2024 | 4,000 | $89.52K | Apr 17, 2024 | Stock Option Exercise |
| Timothy P. Noyes Officer, Director | Apr 16, 2024 | 10,000 | $246.97K | Apr 16, 2024 | Stock Option Exercise |
See a number that looks wrong?